To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Exclusion Criteria

• •1 Subjects who have developed or is currently suffering from other malignancies within 3 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ.
• •2 Subjects who have not recovered to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 due to the adverse event of prior therapy.
• •3 Subjects with significant surgery or significant traumatic injury within 28 days before first injection (excluding needle biopsy or endoscopic biopsy).
• •4 Subjects with long-term unhealed wounds or fractures.
• •5 Subjects with the high risk of bleeding or bleeding history or subjects with bleeding event (≥Common Terminology Criteria for Adverse Events Grade 3) within 4 weeks before first injection.
• •6 Subjects with arterial/venous thrombosis within 6 months.
• •7 Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders.
• •8 Subjects with any severe and/or uncontrolled disease.
• •9 subjects with lymphoma originating from Central Nervous System, high-grade B-cell lymphoma or hemophagocytic syndrome during screening period.
• •10 Subjects with violating Central Nervous System (CNS) .
• •11 Subjects with allogeneic hematopoietic stem cell transplantation.
• •12 Subjects with autologous hematopoietic stem cell transplantation or Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T) within 3 months before first injection.
• •13 Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.